GleamWall
中文EN

AURA Aura Biosciences, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1501796 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-28.6%
TTM EPS YoY16.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-61.7%
ROA-53.5%
ROIC (approx.)-64.7%
Asset turnover—

Leverage & solvency

Liabilities / assets10.6%
Debt / equity0.00x
Current ratio14.21x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.80x
Accruals ratio-10.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$90.30M$73.30M
SG&A expense$22.49M$22.81M
Operating income-$112.79M-$96.12M
Pretax income-$106.08M-$86.81M
Income tax$108,000$112,000
Net income-$106.19M-$86.92M
EBITDA-$111.66M-$94.89M
EPS (basic)-1.76-1.75
EPS (diluted)-1.76-1.75
Weighted avg. shares (diluted)60.34M49.65M
Balance sheet
Cash & equivalents$59.52M$31.69M
Current assets$149.74M$160.62M
PP&E, net$2.62M$3.21M
Total assets$169.43M$182.50M
Current liabilities$18.38M$14.91M
Total liabilities$32.52M$30.53M
Shareholders' equity$136.91M$151.97M
Shares outstanding63.59M50.00M
Cash flow statement
Operating cash flow-$84.74M-$79.81M
Capital expenditure$447,000$1.25M
Free cash flow-$85.19M-$81.06M
Investing cash flow$35.59M$68.82M
Financing cash flow$77.16M$1.59M
Depreciation & amortization$1.13M$1.22M
Stock-based compensation$14.32M$11.72M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.